Zydus Cadila gets tentative USFDA nod for cocktail drug Emtricitabine, Tenofovir Disoproxil Fumarate to treat HIV

Published On 2021-03-26 05:30 GMT   |   Update On 2021-03-26 06:46 GMT
Advertisement

Ahmedabad: Drugmaker, Zydus Cadila, has recently announced that the company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 100 mg/150 mg, 133 mg/200 mg and 167 mg/250 mg (US RLD: TRuvADA Tablets).

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets are used with other HIV medications to help control HIV infection.

Advertisement

This product is a combination of two different drugs: Emtricitabine and Tenofovir Disoproxil Fumarate and helps to decrease the amount of HIV in the body so that the immune system can work better.

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 312 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Read also: Zydus reduces COVID-19 drug Remdesivir price to Rs 899

Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India.
The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.




Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News